| CASE REPORT |
|
| Ahead of Print |
|
|
Role of Cinacalcet in Treating Cardiac Dysfunction Secondary to Hyperparathyroidism: A Case Series
Alpana Ohri1, Samridhi Goyal1, Amish Udani1, Madhukar Gupta2
1 Department of Pediatrics, Division of Pediatric Nephrology, Bai Jerbai Wadia Hospital for Children, Mumbai, Maharashtra, India
2 Department of Urology, Osmania Medical College, Hyderabad, Telangana, India
Correspondence Address:
Samridhi Goyal,
Fellow Pediatric Nephrology, Division of Pediatric Nephrology, Department of Pediatrics, Bai Jerbai Wadia Hospital for Children, Mumbai - 400 012, Maharashtra
India
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/ijn.IJN_262_20
|
|
|
Cardiovascular disease is a leading cause of death in children with chronic kidney disease (CKD). A strong correlation exists between disturbed calcium–phosphate metabolism and cardiac dysfunction. Studies with use of cinacalcet in CKD are few and limited to older children and adults and in improving growth and bone deformities. We present three children with CKD on CAPD with cardiac dysfunction with refractory hyperparathyroidism. Patients were initiated on lowest adult weight-adjusted dose of 0.2 mg/kg/day. Dose was titrated every 30 days to achieve decline in iPTH to a goal of 200– 300 pg/ml. Serum calcium, phosphorus and iPTH levels were checked monthly. Complications of therapy related to cinacalcet monitored. Monthly echocardiography done to monitor cardiac dysfunction. None of them experienced significant adverse effects of cinacalcet therapy.
|
|
|
|
|
|
|
|
Editorial Board
Search Pubmed for
